1.6 -0.01 (-0.62%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.96 ![]() |
1-year : | 2.18 ![]() |
Resists | First : | 1.68 ![]() |
Second : | 1.87 ![]() |
Pivot price | 1.59 ![]() |
|||
Supports | First : | 1.38 | Second : | 1.15 |
MAs | MA(5) : | 1.5 ![]() |
MA(20) : | 1.62 ![]() |
MA(100) : | 2.35 ![]() |
MA(250) : | 3.2 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 43.3 ![]() |
D(3) : | 26.1 ![]() |
RSI | RSI(14): 45.5 ![]() |
|||
52-week | High : | 6.03 | Low : | 1.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ADCT ] has closed below upper band by 48.8%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.72 - 1.73 | 1.73 - 1.74 |
Low: | 1.58 - 1.59 | 1.59 - 1.6 |
Close: | 1.59 - 1.6 | 1.6 - 1.62 |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Sat, 15 Feb 2025
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com
Wed, 12 Feb 2025
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Wed, 12 Feb 2025
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
Mon, 10 Feb 2025
Several ADC Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Mon, 03 Feb 2025
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
Mon, 03 Feb 2025
Strategic Stock Options Grant: ADC Therapeutics Secures Top Talent with 26.8K Share Package - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 97 (M) |
Shares Float | 77 (M) |
Held by Insiders | 20.6 (%) |
Held by Institutions | 61.6 (%) |
Shares Short | 5,180 (K) |
Shares Short P.Month | 4,120 (K) |
EPS | -2.4 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.78 |
Profit Margin | -300 % |
Operating Margin | -192.7 % |
Return on Assets (ttm) | -21.2 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 27.3 % |
Gross Profit (p.s.) | -0.62 |
Sales Per Share | 0.73 |
EBITDA (p.s.) | -1.42 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -134 (M) |
Levered Free Cash Flow | -97 (M) |
PE Ratio | -0.67 |
PEG Ratio | 0 |
Price to Book value | -0.9 |
Price to Sales | 2.18 |
Price to Cash Flow | -1.16 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |